OncoGenex to advance Hsp27 inhibitor in prostate cancer
This article was originally published in Scrip
Executive Summary
OncoGenex Pharmaceuticals has said it is planning to conduct a Phase II study evaluating its investigational Hsp27 inhibitor compound, OGX-427, in combination with Zytiga (Johnson & Johnson's abiraterone) in castrate-resistant prostate cancer after presenting positive preliminary Phase II data for the product.